Analgesic effects of lappaconitine in leukemia bone pain in a mouse model | Zendy

Xiao-Cui Zhu | Zendy; Chen-Tao Ge | Zendy; Pan Wang | Zendy; Jiali Zhang | Zendy; Yuan-Yang Yu | Zendy; Caiyun Fu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Analgesic effects of lappaconitine in leukemia bone pain in a mouse model

Author(s) -

Xiao-Cui Zhu,

Chen-Tao Ge,

Pan Wang,

Jiali Zhang,

Yuan-Yang Yu,

Caiyun Fu

Publication year - 2015

Publication title -

peerj

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.927

H-Index - 70

ISSN - 2167-8359

DOI - 10.7717/peerj.936

Subject(s) - analgesic , bone cancer , medicine , k562 cells , leukemia , bone marrow , apoptosis , endogeny , bone pain , pharmacology , myeloid leukemia , xiap , cancer , anesthesia , chemistry , programmed cell death , biochemistry , caspase

Bone pain is a common and severe symptom in cancer patients. The present study employed a mouse model of leukemia bone pain by injection K562 cells into tibia of mouse to evaluate the analgesic effects of lappacontine. Our results showed that the lappaconitine treatment at day 15, 17 and 19 could effectively reduce the spontaneous pain scoring values, restore reduced degree in the inclined-plate test induced by injection of K562 cells, as well as restore paw mechanical withdrawal threshold and paw withdrawal thermal latency induced by injection of K562 cells to the normal levels. Additionally, the molecular mechanisms of lappaconitine’s analgesic effects may be related to affect the expression levels of endogenous opioid system genes (POMC, PENK and MOR), as well as apoptosis-related genes (Xiap, Smac, Bim, NF- κ B and p53). Our present results indicated that lappaconitine may become a new analgesic agent for leukemia bone pain management.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research